QURIENT CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,690 KRW | -0.14% |
|
-0.54% | -20.99% |
Qurient Co., Ltd. is a Korea-based company mainly engaged in the research and development of pharmaceuticals. The Company includes two programs: development phase programs and research phase programs. The development phase programs consist of Q203 which is drug-resistant tuberculosis treatment drug, Q301 which is atopic dermatitis treatment dug and Q701 which is used for treatment of drug resistant cancer and promotion anti-cancer immunotherapy. The research phase programs consist of 5 lipoxygenase (5LO) inhibit asthma medicines and cyclin dependent kinase 7 (CDK7) inhibit cancer drug.
Sector
Pharmaceuticals
Calendar
12/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.99% | 87.47M | |
| +29.50% | 77.77B | |
| +0.30% | 24.62B | |
| +14.70% | 8.75B | |
| +0.73% | 8.35B | |
| -28.87% | 7.1B | |
| +16.06% | 5.25B | |
| +1.58% | 4.1B | |
| -8.90% | 3.8B | |
| -7.62% | 3.39B |
- Stock Market
- Equities
- A115180 Stock
- Funds and ETFs Qurient Co., Ltd.
